Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

NCT07235527 · clinicaltrials.gov ↗

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Age Related Macular Degeneration
Exudative Age-Related Macular Degeneration
Anti Vascular Endothelial Growth Factor

Interventions

DRUG: Aflibercept biosimilar (MY-1701P)

Sponsor

Saglik Bilimleri Universitesi